SG10201608749UA - Methods of therapeutic monitoring of phenylacetic acid prodrugs - Google Patents

Methods of therapeutic monitoring of phenylacetic acid prodrugs

Info

Publication number: SG10201608749UA
Authority: SG; Singapore
Prior art keywords: methods; phenylacetic acid; therapeutic monitoring; acid prodrugs; prodrugs
Prior art date: 2012-04-20

Application number

SG10201608749UA

Other languages

English (en)

Inventor

Bruce Scharschmidt

Masoud Mokhtarani

Original Assignee

Horizon Therapeutics Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-20

Filing date

2012-09-11

Publication date

2016-12-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49380684&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201608749U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-09-11 Application filed by Horizon Therapeutics Llc filed Critical Horizon Therapeutics Llc

2016-12-29 Publication of SG10201608749UA publication Critical patent/SG10201608749UA/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Emergency Medicine (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Bioinformatics & Computational Biology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)

SG10201608749UA 2012-04-20 2012-09-11 Methods of therapeutic monitoring of phenylacetic acid prodrugs SG10201608749UA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261636256P	2012-04-20	2012-04-20

Publications (1)

Publication Number	Publication Date
SG10201608749UA true SG10201608749UA (en)	2016-12-29

Family

ID=49380684

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201608749UA SG10201608749UA (en)	2012-04-20	2012-09-11	Methods of therapeutic monitoring of phenylacetic acid prodrugs
SG11201406745VA SG11201406745VA (en)	2012-04-20	2012-09-11	Methods of therapeutic monitoring of phenylacetic acid prodrugs

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201406745VA SG11201406745VA (en)	2012-04-20	2012-09-11	Methods of therapeutic monitoring of phenylacetic acid prodrugs

Country Status (25)

Country	Link
US (4)	US9561197B2 (es)
EP (2)	EP3222275B1 (es)
JP (3)	JP6234436B2 (es)
KR (2)	KR102264579B1 (es)
CN (3)	CN104540507A (es)
AU (3)	AU2012377389A1 (es)
BR (1)	BR112014026138A2 (es)
CL (2)	CL2014002807A1 (es)
CY (1)	CY1118838T1 (es)
DK (1)	DK2846791T3 (es)
EC (1)	ECSP14024561A (es)
ES (2)	ES2623470T3 (es)
HK (2)	HK1208380A1 (es)
HR (1)	HRP20170651T1 (es)
HU (1)	HUE032726T2 (es)
IL (2)	IL235127A (es)
LT (1)	LT2846791T (es)
MX (1)	MX365302B (es)
PL (1)	PL2846791T3 (es)
PT (1)	PT2846791T (es)
RS (1)	RS55870B1 (es)
SG (2)	SG10201608749UA (es)
SI (1)	SI2846791T1 (es)
WO (1)	WO2013158145A1 (es)
ZA (1)	ZA201407597B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2760479T3 (pl)	2011-09-30	2017-09-29	Horizon Therapeutics, Llc	Lek wychwytujący azot do zastosowania w sposobie leczenia zaburzenia retencji azotu
EP3222275B1 (en)	2012-04-20	2020-06-24	Immedica Pharma AB	Methods of therapeutic monitoring of phenylacetic acid prodrugs
CA2891657A1 (en) *	2012-11-21	2014-05-30	Bruce Scharschmidt	Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
WO2015057747A1 (en)	2013-10-14	2015-04-23	Hyperion Therapeutics, Inc.	Methods of treating urea cycle disorders
ES2748294T3 (es) *	2014-06-04	2020-03-16	Immedica Pharma Ab	Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre
US9914692B2 (en)	2016-05-25	2018-03-13	Horizon Therapeutics, Llc	Procedure for the preparation of 4-phenyl butyrate and uses thereof
US20190076383A1 (en) *	2017-09-08	2019-03-14	Horizon Therapeutics, Llc	Methods for treating urea cycle disorders
US10668040B2 (en)	2017-09-11	2020-06-02	Horizon Therapeutics, Llc	Treatment of urea cycle disorders in neonates and infants

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4284647A (en)	1980-03-31	1981-08-18	The Johns Hopkins University	Process for waste nitrogen removal
US4457942A (en)	1982-08-20	1984-07-03	Brusilow Saul W	Process for waste nitrogen removal
US5635532A (en)	1991-10-21	1997-06-03	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US5879657A (en)	1993-03-30	1999-03-09	The Dupont Merck Pharmaceutical Company	Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
ATE201013T1 (de)	1995-02-07	2001-05-15	Brusilow Entpr Llc	Triglyceride und ethylester von phenylalkansäuren und phenylalkensäuren zur behandlung verschiedener erkrankungen
US6219567B1 (en)	1999-06-21	2001-04-17	Cardiox Corporation	Monitoring of total ammoniacal concentration in blood
US20040229948A1 (en)	2002-04-12	2004-11-18	Summar Marshall L.	Method for preventing hepatic encephalopathic episodes
US20030195255A1 (en)	2002-04-12	2003-10-16	Summar Marshall L.	Method for treating hepatic encephalopathies
US20050273359A1 (en)	2004-06-03	2005-12-08	Young David E	System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure
EA011716B1 (ru)	2004-11-26	2009-04-28	Ю Си Эл БИЗНЕС Пи Эл Си	Композиция, содержащая орнитин и фенилацетат или фенилбутират, для лечения печеночной энцефалопатии
US20060135612A1 (en)	2004-12-17	2006-06-22	U.S. Department Of Veterans Affairs	Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US20070004805A1 (en)	2005-07-01	2007-01-04	Navinta Llc	Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
WO2007059031A2 (en)	2005-11-10	2007-05-24	Massachusetts Institute Of Technology	Methods and compositions for raising levels and release of gamma aminobutyric acid
US8094521B2 (en)	2007-02-28	2012-01-10	Nightingale Products LLC	Caregiver personal alert device
GB2451259B (en) *	2007-07-25	2011-07-20	Gp Acoustics	Loudspeaker
CN101959429B (zh)	2008-01-08	2014-09-10	阿克塞利亚制药公司	抗微生物肽***的激动剂
EP3133396B1 (en)	2008-04-29	2018-09-05	Horizon Therapeutics, LLC	Methods of treatment using ammonia-scavenging drugs
HUE029912T2 (en) *	2008-08-29	2017-03-28	Horizon Therapeutics Llc	Treatments using an ammonia binding agent
EP2338050A1 (en) *	2008-08-29	2011-06-29	Ucyclyd Pharma, Inc.	Dosing and monitoring patients on nitrogen-scavenging drugs
WO2011011781A1 (en)	2009-07-24	2011-01-27	Baylor College Of Medicine	Methods of modulation of branched chain acids and uses thereof
EP2611470B1 (en)	2010-08-31	2017-08-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation
PL2760479T3 (pl)	2011-09-30	2017-09-29	Horizon Therapeutics, Llc	Lek wychwytujący azot do zastosowania w sposobie leczenia zaburzenia retencji azotu
EP3222275B1 (en)	2012-04-20	2020-06-24	Immedica Pharma AB	Methods of therapeutic monitoring of phenylacetic acid prodrugs
CA2891657A1 (en)	2012-11-21	2014-05-30	Bruce Scharschmidt	Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy

2012
- 2012-09-11 EP EP17154858.9A patent/EP3222275B1/en active Active
- 2012-09-11 CN CN201280074143.6A patent/CN104540507A/zh active Pending
- 2012-09-11 DK DK12874745.8T patent/DK2846791T3/en active
- 2012-09-11 HU HUE12874745A patent/HUE032726T2/en unknown
- 2012-09-11 KR KR1020197029026A patent/KR102264579B1/ko active IP Right Grant
- 2012-09-11 ES ES12874745.8T patent/ES2623470T3/es active Active
- 2012-09-11 SG SG10201608749UA patent/SG10201608749UA/en unknown
- 2012-09-11 US US13/610,580 patent/US9561197B2/en active Active
- 2012-09-11 ES ES17154858T patent/ES2807951T3/es active Active
- 2012-09-11 RS RS20170421A patent/RS55870B1/sr unknown
- 2012-09-11 LT LTEP12874745.8T patent/LT2846791T/lt unknown
- 2012-09-11 PT PT128747458T patent/PT2846791T/pt unknown
- 2012-09-11 BR BR112014026138A patent/BR112014026138A2/pt not_active Application Discontinuation
- 2012-09-11 SG SG11201406745VA patent/SG11201406745VA/en unknown
- 2012-09-11 KR KR1020147032114A patent/KR20150013170A/ko not_active IP Right Cessation
- 2012-09-11 CN CN202010449455.7A patent/CN111991383A/zh active Pending
- 2012-09-11 PL PL12874745T patent/PL2846791T3/pl unknown
- 2012-09-11 SI SI201230933A patent/SI2846791T1/sl unknown
- 2012-09-11 MX MX2014012694A patent/MX365302B/es active IP Right Grant
- 2012-09-11 EP EP12874745.8A patent/EP2846791B1/en active Active
- 2012-09-11 WO PCT/US2012/054673 patent/WO2013158145A1/en active Application Filing
- 2012-09-11 CN CN202111191403.5A patent/CN113995743A/zh active Pending
- 2012-09-11 AU AU2012377389A patent/AU2012377389A1/en not_active Abandoned
- 2012-09-11 JP JP2015506953A patent/JP6234436B2/ja active Active
2014
- 2014-10-17 CL CL2014002807A patent/CL2014002807A1/es unknown
- 2014-10-19 IL IL235127A patent/IL235127A/en active IP Right Grant
- 2014-10-20 ZA ZA2014/07597A patent/ZA201407597B/en unknown
- 2014-10-27 EC ECIEPI201424561A patent/ECSP14024561A/es unknown
2015
- 2015-09-18 HK HK15109202.8A patent/HK1208380A1/xx unknown
2017
- 2017-01-10 US US15/402,780 patent/US20170266143A1/en not_active Abandoned
- 2017-04-20 CY CY20171100449T patent/CY1118838T1/el unknown
- 2017-04-27 HR HRP20170651TT patent/HRP20170651T1/hr unknown
- 2017-05-30 CL CL2017001375A patent/CL2017001375A1/es unknown
- 2017-08-25 US US15/687,136 patent/US20180015058A1/en not_active Abandoned
- 2017-10-24 JP JP2017204831A patent/JP6637941B2/ja active Active
- 2017-11-26 IL IL255918A patent/IL255918B/en active IP Right Grant
2018
- 2018-01-09 AU AU2018200163A patent/AU2018200163B2/en active Active
- 2018-03-15 HK HK18103625.7A patent/HK1243959A1/zh unknown
- 2018-05-15 US US15/980,431 patent/US20180263938A1/en not_active Abandoned
2019
- 2019-03-15 AU AU2019201811A patent/AU2019201811B2/en active Active
- 2019-08-19 JP JP2019149843A patent/JP2019219413A/ja active Pending

Also Published As

Publication number	Publication date
PL2846791T3 (pl)	2017-07-31
IL255918B (en)	2019-06-30
RS55870B1 (sr)	2017-08-31
AU2019201811B2 (en)	2020-07-09
SG11201406745VA (en)	2014-12-30
JP2018039830A (ja)	2018-03-15
CL2014002807A1 (es)	2015-02-27
AU2018200163A1 (en)	2018-02-01
US20180015058A1 (en)	2018-01-18
US9561197B2 (en)	2017-02-07
KR20190116552A (ko)	2019-10-14
US20130281530A1 (en)	2013-10-24
SI2846791T1 (sl)	2017-06-30
CN104540507A (zh)	2015-04-22
IL235127A (en)	2017-12-31
KR20150013170A (ko)	2015-02-04
CL2017001375A1 (es)	2018-01-05
ES2623470T3 (es)	2017-07-11
ES2807951T3 (es)	2021-02-24
HK1208380A1 (en)	2016-03-04
WO2013158145A9 (en)	2014-05-01
CN113995743A (zh)	2022-02-01
ZA201407597B (en)	2017-05-31
US20170266143A1 (en)	2017-09-21
CY1118838T1 (el)	2018-01-10
JP6637941B2 (ja)	2020-01-29
JP2015514757A (ja)	2015-05-21
EP2846791A1 (en)	2015-03-18
WO2013158145A1 (en)	2013-10-24
ECSP14024561A (es)	2015-09-30
DK2846791T3 (en)	2017-03-27
EP2846791B1 (en)	2017-02-08
AU2019201811A1 (en)	2019-04-04
AU2018200163B2 (en)	2018-12-20
BR112014026138A2 (pt)	2017-06-27
US20180263938A1 (en)	2018-09-20
PT2846791T (pt)	2017-05-25
HK1243959A1 (zh)	2018-07-27
EP2846791A4 (en)	2015-08-19
HUE032726T2 (en)	2017-10-30
JP2019219413A (ja)	2019-12-26
MX365302B (es)	2019-05-29
EP3222275A1 (en)	2017-09-27
LT2846791T (lt)	2017-04-10
JP6234436B2 (ja)	2017-11-22
AU2012377389A1 (en)	2014-10-30
IL255918A (en)	2018-01-31
HRP20170651T1 (hr)	2017-06-30
CN111991383A (zh)	2020-11-27
EP3222275B1 (en)	2020-06-24
MX2014012694A (es)	2015-06-03
KR102264579B1 (ko)	2021-06-11

Publication	Publication Date	Title
HRP20190420T1 (hr)	2019-04-19	Postupci proizvodnje akrilne kiseline
HK1243959A1 (zh)	2018-07-27	苯乙酸前藥的治療性檢測方法
HK1209793A1 (en)	2016-04-08	Methods of detecting diseases or conditions
HK1205697A1 (en)	2015-12-24	Prodrugs of hydroxyl-comprising drugs
EP2802381A4 (en)	2015-02-18	PHOTOTHERAPY SURVEILLANCE
GB201110403D0 (en)	2011-08-03	Monitoring of conduits
HK1216361A1 (zh)	2016-11-04	電池組件系統
HK1199095A1 (en)	2015-06-19	Methods for monitoring responsiveness to anti-smad7 therapy smad7
EP2817531A4 (en)	2015-11-25	MONITORING BRAKES
EP2866854A4 (en)	2016-03-30	METHODS OF USING POLYMERS
HK1197230A1 (en)	2015-01-09	Epoxyeicosatrienoic acid analogs and methods of making and using the same
EP2745235A4 (en)	2015-05-27	METHOD FOR REPOSITIONING MEDICATION
GB201111396D0 (en)	2011-08-17	Monitoring of livestock
PT2934134T (pt)	2019-12-03	Utilizações de inalação de ácido acetilsalicílico
EP2888227A4 (en)	2016-06-22	NEW PRODRUGS AND METHODS OF USE
IL236965B (en)	2019-03-31	Derivatives of 5-aminolevulinic acid and uses thereof
GB201220155D0 (en)	2012-12-26	Method of manufacture
GB2506475B (en)	2014-11-19	Parameter setting method of tire monitor
ZA201500488B (en)	2016-11-30	Manufacture of wheels
HK1214587A1 (zh)	2016-07-29	肉桂酰胺衍生物
EP2782902A4 (en)	2015-08-26	DERIVATIVES FROM PHENOXYISOBUTTERIC ACID
ZA201308320B (en)	2015-01-28	Epoxyeicosatrienoic acid analogs and methods of making and using the same
GB201105944D0 (en)	2011-05-18	Resuscitation monitoring system